GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Serina Therapeutics Inc (AMEX:SER) » Definitions » Gross-Profit-to-Asset %

Serina Therapeutics (Serina Therapeutics) Gross-Profit-to-Asset % : 0.00% (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Serina Therapeutics Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Serina Therapeutics's annualized Gross Profit for the quarter that ended in Mar. 2024 was $0.00 Mil. Serina Therapeutics's average Total Assets over the quarter that ended in Mar. 2024 was $10.30 Mil. Therefore, Serina Therapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 0.00%.


Serina Therapeutics Gross-Profit-to-Asset % Historical Data

The historical data trend for Serina Therapeutics's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Serina Therapeutics Gross-Profit-to-Asset % Chart

Serina Therapeutics Annual Data
Trend Dec21 Dec22
Gross-Profit-to-Asset %
164.80 37.01

Serina Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Mar24
Gross-Profit-to-Asset % - 54.23 - - -

Competitive Comparison of Serina Therapeutics's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Serina Therapeutics's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Serina Therapeutics's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Serina Therapeutics's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Serina Therapeutics's Gross-Profit-to-Asset % falls into.



Serina Therapeutics Gross-Profit-to-Asset % Calculation

Serina Therapeutics's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2022 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2022 )/( (Total Assets (A: Dec. 2021 )+Total Assets (A: Dec. 2022 ))/ count )
=0.5/( (1.844+0.858)/ 2 )
=0.5/1.351
=37.01 %

Serina Therapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Mar. 2024 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=0/( (9.739+10.856)/ 2 )
=0/10.2975
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Mar. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Serina Therapeutics Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Serina Therapeutics's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Serina Therapeutics (Serina Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
Address
601 Genome Way, Suite 2001, Huntsville, AL, USA, 35806
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers.

Serina Therapeutics (Serina Therapeutics) Headlines